SCHEMBL1193365

SCHEMBL1193365

CCOC(=O)c1cnn(-c2nc3cc(Nc4ccccc4)c(Cl)cc3n2COCCOC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 3/20 0.44
PTGER4 P35408 3/20 0.37
EGFR P00533 2/20 0.37
KDR P35968 1/20 0.37
GAA P10253 2/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
ERBB2 P04626 1/20 0.36
RAB9A P51151 2/20 0.36
CYP1A2 P05177 2/20 0.36
MAPT P10636 4/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
TP53 P04637 2/20 0.36
NPC1 O15118 1/20 0.36
ABCB1 P08183 1/20 0.36
HTT P42858 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1193440 0.89 EGLN1 (0.47) EGLN1PTGER4EGFRERBB2RAB9A
SCHEMBL1193469 0.88 EGLN1 (0.45) EGLN1PTGER4ALDH1A1KDM4E
SCHEMBL1193636 0.87 EGLN1 (0.42) EGLN1PTGER4RAB9ACYP1A2ALDH1A1
SCHEMBL1193012 0.87 EGLN1 (0.45) EGLN1PTGER4GAAUSP2TSHR
SCHEMBL1192795 0.85 EGLN1 (0.39) EGLN1PTGER4GAAUSP2TSHR
SCHEMBL1193143 0.85 EGLN1 (0.44) EGLN1PTGER4GAAUSP2TSHR
SCHEMBL1192982 0.84 PTGER4 (0.36) EGLN1PTGER4RAB9AMAPTMEN1
SCHEMBL1193033 0.84 EGLN1 (0.38) EGLN1PTGER4MAPTNPC1SIRT2
SCHEMBL1192157 0.83 EGLN1 (0.47) EGLN1PTGER4GAAUSP2TSHR
SCHEMBL1193437 0.83 EGLN1 (0.46) EGLN1PTGER4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2023-04-04 US disclosed
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-03-18 US disclosed
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-12-01 US disclosed
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-08-02 US disclosed
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-25 US disclosed
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-06-16 US disclosed
US-9073923-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-07 US disclosed
EP-2294066-B9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-03-11 EP disclosed
US-8865713-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-10-21 US disclosed
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-09-11 US disclosed
EP-2294066-B1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 EP disclosed
US-8759345-B2 Benzoimidazoles as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-06-24 US disclosed
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2014-01-02 US disclosed
EP-2294066-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2011-03-16 EP disclosed
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-02-24 US disclosed
WO-2009134750-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11618744-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885
US-20110046132-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 10/4885PTGER4 1439/4885EGFR 3707/4885
US-20180022733-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885
US-20140005193-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885
US-10851083-B2 Benzoimidazoles as prolyl hydroxylase inhibitors P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885
US-20180215732-A9 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885
US-20140256722-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885
US-20210078978-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885
US-20160168127-A1 BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 8/4885PTGER4 1543/4885EGFR 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.